Table 2.

Screening Pap results, final biopsy diagnosis, and referral to treatment for the 152 patients who completed diagnostic follow-up

Mobile vanCentral facility
No. patients10052
Presenting Pap diagnosis, no. patients (%)Pa
 ASC-US36 (36)13 (25)0.18
 ASC-H23 (23)13 (25)
 LSIL26 (26)10 (19)
 HSIL12 (12)13 (25)
 AGC3 (3)3 (6)
Final biopsy diagnosis, no. patients (%)P
 Benign40 (40)17 (33)0.27
 CIN130 (30)13 (25)
 CIN214 (14)7 (13)
 CIN311 (11)14 (27)
 Adenocarcinoma in situ1 (1)0 (0)
 Invasive carcinoma2 (2)1 (2)
 Indeterminate2 (2)0 (0)
Referral to treatment, no. patients (%)P
 Follow-up63 (63)29 (56)0.11
 Cryotherapy (only offered in mobile van arm)6 (6)0 (0)
 LEEP29 (29)20 (38)
 Cancer management2 (2)3 (6)
  • NOTE: Treatment and/or follow-up information reflects management recommendations, which in some cases may differ from treatment and/or follow-up actually received (except in the case of cryotherapy in the mobile van arm, which was performed immediately).

  • Abbreviations: AGC, atypical glandular cells; ASC-H, atypical squamous cells, cannot exclude HSIL; ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excision procedure; LSIL, low-grade squamous intraepithelial lesion.

  • aP values calculated using Fisher's exact test. P values compare the populations in the two arms of the study in terms of presenting Pap diagnosis, final biopsy diagnosis, and referral to treatment. No statistically significant difference was observed between the populations in terms of those categories (P > 0.05).